Outcome of hospitalization for COVID-19 in patients with interstitial lung disease. An international multicenter study
…, W Chang, A Crawshaw, LE Crowley… - American journal of …, 2020 - atsjournals.org
Rationale: The impact of coronavirus disease (COVID-19) on patients with interstitial lung
disease (ILD) has not been established. Objectives: To assess outcomes in patients with ILD …
disease (ILD) has not been established. Objectives: To assess outcomes in patients with ILD …
The burden of progressive fibrotic interstitial lung disease across the UK
…, N Chaudhuri, A Crawshaw, LE Crowley… - European …, 2021 - Eur Respiratory Soc
While idiopathic pulmonary fibrosis (IPF) remains the exemplar progressive fibrotic lung
disease, there remains a cohort of non-IPF fibrotic lung diseases (fILD) which adopt a similar …
disease, there remains a cohort of non-IPF fibrotic lung diseases (fILD) which adopt a similar …
[HTML][HTML] Dysregulated neutrophil phenotype and function in hospitalised non-ICU COVID-19 pneumonia
Rationale: Infection with the SARS-CoV2 virus is associated with elevated neutrophil counts.
Evidence of neutrophil dysfunction in COVID-19 is based on transcriptomics or single …
Evidence of neutrophil dysfunction in COVID-19 is based on transcriptomics or single …
Real-world retrospective observational study exploring the effectiveness and safety of antifibrotics in idiopathic pulmonary fibrosis
WA Wright, LE Crowley, D Parekh… - BMJ open …, 2021 - bmjopenrespres.bmj.com
Background Pirfenidone and nintedanib are the only disease-modifying treatments available
for idiopathic pulmonary fibrosis (IPF). Our aim was to test their effectiveness and safety in …
for idiopathic pulmonary fibrosis (IPF). Our aim was to test their effectiveness and safety in …
[HTML][HTML] Role of CD248 as a potential severity marker in idiopathic pulmonary fibrosis
D Bartis, LE Crowley, VK D'Souza, L Borthwick… - BMC Pulmonary …, 2016 - Springer
Background CD248 or Endosialin is a transmembrane molecule expressed in stromal cells
binding to extracellular matrix (ECM) components. It has been previously implicated in …
binding to extracellular matrix (ECM) components. It has been previously implicated in …
Characterisation and outcomes of ARDS secondary to pneumonia in patients with and without SARS-CoV-2: a single-centre experience
…, R Desai, E Beesley, LE Crowley… - BMJ open …, 2020 - bmjopenrespres.bmj.com
Introduction Acute respiratory distress syndrome (ARDS) is the major cause of mortality in
patients with SARS-CoV-2 pneumonia. It appears that development of ‘cytokine storm’ in …
patients with SARS-CoV-2 pneumonia. It appears that development of ‘cytokine storm’ in …
[HTML][HTML] Utility of severity assessment tools in COVID-19 pneumonia: a multicentre observational study
…, BL Barker, R Bhat, S Cassidy, LE Crowley… - Clinical …, 2022 - ncbi.nlm.nih.gov
Background Severity scores in pneumonia and sepsis are being applied to SARS-CoV-2
infection. We aimed to assess whether these severity scores are accurate predictors of early …
infection. We aimed to assess whether these severity scores are accurate predictors of early …
[HTML][HTML] Domestic violence in the Solomon Islands
…, RE Tiller, RG Rice, LE Crowley… - Journal of family …, 2016 - journals.lww.com
The Solomon Islands has one of the highest rates of family and sexual violence (FSV) in the
world with 64% of women aged 15–49 have reported physical and/or sexual abuse by a …
world with 64% of women aged 15–49 have reported physical and/or sexual abuse by a …
[HTML][HTML] Anti-acid therapies in idiopathic pulmonary fibrosis: premature to dismiss?
LE Crowley, A Wilson, DR Thickett - American Journal of Respiratory …, 2022 - atsjournals.org
We read with great interest the latest “Idiopathic Pulmonary Fibrosis (an Update) and Progressive
Pulmonary Fibrosis in Adults” official American Thoracic Society/European Respiratory …
Pulmonary Fibrosis in Adults” official American Thoracic Society/European Respiratory …
[HTML][HTML] Real-world experience of nintedanib for progressive fibrosing interstitial lung disease in the UK
…, J Chalmers, A Crawshaw, LE Crowley… - ERJ Open …, 2024 - Eur Respiratory Soc
Background Nintedanib slows progression of lung function decline in patients with progressive
fibrosing (PF) interstitial lung disease (ILD) and was recommended for this indication …
fibrosing (PF) interstitial lung disease (ILD) and was recommended for this indication …
